0,31 CME

Pengujian HPV sebagai Pemeriksaan Primer dan Skrining Kanker Serviks

Pembicara: Dr. Zuhdi Khalid

Alumni- Universitas King Saud

Masuk untuk Memulai

Keterangan

HPV testing used as a primary screening tool for cervical cancer. We will explore the advancements in HPV testing and its impact on cervical cancer prevention. Understanding the importance of primary screening and the role of HPV testing is crucial in reducing the burden of cervical cancer.  Cervical cancer is a significant global health issue, affecting women worldwide. It is the fourth most common cancer in women, with a high mortality rate in developing countries. Early detection through effective screening methods is crucial for reducing the burden of cervical cancer. Traditional methods such as Pap smears have been used for screening, but advancements in HPV testing have revolutionized primary screening. There are various types of HPV, including high-risk strains associated with the development of cervical cancer. Understanding the link between HPV infection and cervical cancer is vital for effective screening strategies.

Ringkasan

  • In the UAE, cervical cancer ranks as the seventh most prevalent cancer among women and the sixth leading cause of cancer-related deaths. Notably, the incidence of cervical cancer is on the rise, especially in developing countries.
  • Cervical cancer screening programs have demonstrated effectiveness in lowering the incidence of the disease, provided they are implemented effectively. HPV testing, when used as a primary screening method, exhibits high sensitivity and an exceptionally high negative predictive value.
  • HPV testing coupled with HPV integration is expected to provide a more accurate and sensitive assessment of the risk of developing cervical cancer in the near future.
  • The Athena trial involved 47,000 women and followed them for three years. It showed that HPV screening in women over 20 is as effective as a hybrid screening strategy using cytology if they are 25 to 28 years old and co-testing if they are older than 30.
  • The Kobas HPV test is FDA-approved for primary cervical screening and identifies HPV 16 and 18 genotypes with high-risk HPV co-testing. There is no consensus on cervical screening guidelines between Europe and America.

Komentar